PIIL:SEC:NSE/BSE:41:2026-27
August 14, 2026

BSE Limited Corporate Relationship Department PJ Towers, 25th Floor, Dalal Street, Mumbai – 400 001 **Code No.523642**	National Stock Exchange of India Ltd. Exchange Plaza, Plot No.C/1, G-Block Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 **Code No. PIIND**

Dear Sir /Ma'am,

Sub: Summary of the proceedings of the 79th Annual General Meeting ('AGM') of the Company held on August 14, 2026

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a summary of the proceedings of the AGM of the Company held today i.e., Friday, August 14, 2026 at 10.30 A.M. (IST) through Video Conference ('VC') / Other Audio-Visual Means ('OAVM').

This is for your information and record please.
Thanking you,

Yours faithfully,
For **PI Industries Limited**

SHRUTI RATNAKAR JOSHI
Digitally signed by SHRUTI RATNAKAR JOSHI
Date: 2026.08.14 18:07:03 +05'30'

Shruti Joshi
Company Secretary and Compliance Officer

Encl: As above.

Registered Office:
PI Industries Limited
Udaisagar Road, Udaipur - 313001, Rajasthan, India.
Tel.: 0294 6651100, 2492451 – 55 | **CIN:** L24211RJ1946PLC000469
info@piind.com www.piindustries.com

Summary of proceedings of the 79th Annual General Meeting ('AGM') of PI Industries Limited

The 79th AGM of PI Industries Limited ('the Company') was held on Friday, August 14, 2026 at 10.30 a.m. (IST), through Video Conference ('VC') / Other Audio-Visual Means ('OAVM').

Members present through VC / OAVM: 88

Mr. Narayan K Seshadri, Chairperson presided over the meeting and welcomed the members. The requisite quorum being present, the Chairperson called the meeting to order. The Chairperson informed the Members that the Company had provided the facility of two-way video conferencing of the proceedings of this AGM which could be viewed live by the members by logging on the website of the Registrar, KFin Technologies Limited ('Kfin').

The Chairperson introduced the Directors, the Chief Financial Officer and the Company Secretary. He informed that the authorized representatives of the Statutory Auditor, the Secretarial Auditor, the Cost Auditor and the Scrutinizer, were also present virtually for this meeting. It was informed that, there were no observations, qualifications or comments either by the Statutory Auditors, the Secretarial Auditor and the Cost Auditor in their respective reports having any adverse effect on the functioning of the Company and hence, their reports were not required to be read. With the permission of the shareholders, Notice convening this AGM was taken as read.

The presence of the Chairperson of Audit Committee, Stakeholders Relationship Committee and Nomination & Remuneration Committee, was also confirmed.

With the permission of the shareholders, the notice convening this AGM was taken as read. The Chairperson informed that all the relevant documents and registers referred in the Notice calling the AGM pursuant to the Companies Act, 2013 ('the Act') read with Secretarial Standard on General Meetings were made available for inspection by the shareholder's electronically on the website of KFin, throughout the duration of the AGM proceedings.

The Chairperson, then proceeded to address the shareholders on the performance of the Company for the financial year 2025-26 and the outlook for the next year. The same is enclosed herewith as **Annexure- A.**
The Chairperson informed the members that item No. 1 to 9 of the Notice have been voted by the members through remote e-voting from August 10, 2026 to August 13, 2026. The members present at the meeting who have not participated in remote e-voting, were allowed to cast their votes using e-voting platform of KFin.

It was informed that Mr. Ashish K Friends, Practicing Company Secretary, has been appointed by the Board of Directors of the Company as the Scrutinizer for scrutinizing the remote e-voting and e-voting process during the AGM in a fair and transparent manner.

Nine of the members who had registered themselves as speaker shareholders were invited to express their views and queries. The queries raised by them were suitably replied to by the Chairperson and Mr. Mayank Singhal, Vice Chairperson and Managing Director.

The following business items as set out in the Notice convening the 79th AGM were recommended for the consideration and approval of the members:

S. No.	Agenda Items	Type of Resolution
ORDINARY BUSINESS		
1.	To consider and adopt the financial statements (standalone and consolidated) of the Company for the financial year ended March 31, 2026, together with the reports of Board of Directors and Auditors thereon	Ordinary Resolution
2.	To confirm the payment of Interim Dividend of Rs. 5.00 per equity share of face value of Re. 1.00 each and to declare Final Dividend of Rs. 10.00 per equity share of face value of Re. 1.00 each for the financial year ended March 31, 2026.	Ordinary Resolution
3.	To appoint a director in place of Mr. Rafael Del Rio Donoso (DIN: 08105128), who retires by rotation and being eligible, offers his candidature for re-appointment.	Ordinary Resolution
SPECIAL BUSINESS		
4.	Non-filling of vacancy caused by retirement of Mr. Arvind Singhal (DIN: 00092425), Non-Executive Non-Independent Director	Ordinary Resolution
5.	Ratification of remuneration payable to Cost Auditor for the financial year 2026-27	Ordinary Resolution
6.	Remuneration payable to Mr. Rafael Del Rio Donoso (DIN: 08105128), a Non-Executive Non-Independent Director of the Company	Ordinary Resolution
7.	Appointment of Dr. Atul Kumar Gupta (DIN: 10087955) as a Director and Whole Time Director of the Company	Special Resolution
8.	Re-appointment of Mr. Shobinder Duggal (DIN: 00039580) as an Independent Director of the Company	Special Resolution
9.	Re-appointment of Ms. Pia Singh (DIN: 00067233) as an Independent Director of the Company	Special Resolution

The Chairperson informed the members that e-voting was kept open throughout the AGM and 15 minutes after the conclusion of the meeting. The meeting ended with vote of thanks to the Chair.

All the aforesaid business items at Resolution nos. 1 to 9 contained in the notice convening the AGM have been passed with the requisite majority.

This is for your information and records.

Thanking you,

Yours faithfully,
For **PI Industries Limited**

SHRUTI RATNAKAR JOSHI
Digitally signed by SHRUTI RATNAKAR JOSHI
Date: 2026.08.14 18:07:31 +05'30'

Shruti Joshi
Company Secretary and Compliance Officer

Annexure - A

PI Industries Limited
Chairman's Speech – 79th Annual General Meeting

Good morning, Ladies and Gentlemen, esteemed Shareholders, and my fellow Members of the Board.

It gives me great pleasure to welcome you all to the **79th Annual General Meeting of PI Industries Limited.** On behalf of the Board of Directors, I thank you for your continued trust, confidence and support. Your belief in our vision and long-term strategy has helped us navigate a challenging year while building a stronger and more resilient organisation.

Financial year 2025-26 unfolded against a volatile global backdrop. The agrochemical industry faced demand softness across key markets, pricing pressures, geopolitical uncertainty and an evolving regulatory landscape – factors that weighed on growth and profitability across the value chain and created near-term challenges for businesses worldwide.

Despite these headwinds, PI Industries stayed focused on its long-term strategic priorities: investing in innovation, strengthening our portfolio, expanding capabilities across emerging growth platforms, and advancing our transformation from a leading agri-sciences company into a diversified life sciences enterprise.

Our theme, "Pioneering Innovation in Life Sciences from India to the World," reflects our commitment to using science, technology and sustainability to deliver meaningful solutions for customers and society, while creating sustainable value for all stakeholders.

The Integrated Annual Report for the year ended March 31, 2026, has been circulated to shareholders, and I trust you have had the opportunity to review it. With your permission, I would like to share some of the year's key highlights.

Performance Highlights

FY 2025-26 was a year of resilience and disciplined execution in a challenging industry environment.

On a consolidated basis, your Company reported revenue from operations of ₹67,137 million and Profit After Tax of ₹13,208 million. This performance reflects the continued pressures within the global agrochemical sector. We delivered a consolidated gross margin of approximately 58% and an EBITDA margin of 25.4%, underscoring the strength of our product portfolio, operational discipline and improved product mix.

Agrochemicals remained the anchor of our business, while growing momentum in Biologicals, Health Sciences and other specialty segments further strengthened our portfolio and positioned us for the next phase of growth.

In line with our commitment to shareholder value, the Board declared an interim dividend of ₹5 per equity share and has recommended a final dividend of ₹10 per equity share – taking the total dividend for FY 2025-26 to ₹15 per equity share, subject to your approval at this meeting.

Commitment to Innovation

Innovation remains the foundation of PI's business model and a key differentiator in an increasingly competitive market.

Through the year, we strengthened our innovation ecosystem with sustained investment in research and development, intellectual property creation and advanced technology platforms. This agenda spans crop protection, biologicals, pharma CRDMO and specialty chemicals, enabling us to develop differentiated, sustainable solutions across multiple industries.

A significant milestone was the continued progress of Pioxaniliprole, India's first indigenously discovered crop protection molecule. We are proud to be the first Indian company to receive Indian Standards Organisation approval for this innovative molecule – a testament to our scientific capabilities and regulatory excellence. During the year, we advanced the project through extensive Kharif and Rabi field demonstrations, generating valuable performance data and stakeholder engagement. The programme has advanced through extensive Kharif trials, to be followed by licensing and regulatory approval – bringing us closer to commercialising this landmark innovation.

We also continued investing in next-generation chemistry platforms, green chemistry initiatives, digital technologies and process innovation to drive operational excellence and build sustainable competitive advantage.

As we expand beyond traditional agri-sciences, our innovation capabilities are increasingly the cornerstone for future growth across Biologicals, Pharma CRDMO, Electronic Chemicals and other high-value specialty segments.

Strategic Transformation and New Growth Platforms

Our strategic transformation gathered further momentum in FY 2025-26.

Agchem remained the core of our business during the year. Our order book stayed stable, reflecting the strength of our customer relationships and innovation-led model. We commercialised five new molecules, further strengthening our portfolio and supporting future growth.

Our Agri Brands business operated in a challenging environment marked by weather-related disruptions and lower crop prices. Despite this, we launched four new products and advanced a strong development pipeline, positioning the business for long-term growth.

Our Biologicals platform achieved a significant milestone with US EPA registration and the commercial launch of our foliar bionematicide – the world's first foliar-applied biological solution for nematode management. This breakthrough expands our opportunities across key global agricultural markets and reinforces our commitment to sustainable crop solutions.

Our Health Sciences business achieved growth momentum during the year, with revenue growing 40%. As a trusted CRDMO partner to global pharmaceutical and biotechnology companies, we continued to strengthen our research, development and manufacturing capabilities, enabling us to better serve customer requirements and capitalize on emerging industry trends.

Together, these businesses are important pillars of our long-term growth strategy, reinforcing our ambition to build a diversified life sciences portfolio that is resilient, innovation-driven and globally relevant.

Sustainability, ESG and CSR

At PI Industries, innovation, science and sustainability reinforce one another and together drive responsible growth. Sustainability is deeply embedded across our business strategy, product development, manufacturing operations and stakeholder engagement.

Our focus on responsible chemistry, resource efficiency, circular economy principles, water stewardship and energy optimisation reflects our commitment to long-term environmental and social value. We remain focused on reducing our environmental footprint while enhancing operational efficiency and competitiveness.

We continue to invest in green chemistry platforms, digital transformation and advanced manufacturing technologies that support both growth and sustainability. Through responsible sourcing, process innovation and environmental stewardship, we are building a robust foundation for a low-carbon, resource-efficient future.

Good governance remains central to our business philosophy. We continue to strengthen our governance and risk management frameworks while upholding the highest standards of ethics, transparency and accountability.

This commitment extends beyond our operations to the communities we serve. Through our CSR initiatives, we support programmes in education, healthcare, water conservation, rural development and livelihood enhancement – creating meaningful social impact and contributing to inclusive, sustainable development.

People and Culture

Our people remain our greatest strength and the driving force behind every success we achieve. I want to thank all our employees for their commitment, resilience and passion in a year that tested the entire industry. Their dedication enabled PI to navigate challenges while continuing to build future-ready capabilities and growth platforms.

We remain committed to a culture rooted in safety, integrity, innovation, collaboration and excellence, and continue to invest in leadership development, talent management, capability building and employee well-being to keep our workforce agile, engaged and future-ready.

Our efforts to strengthen diversity, equity and inclusion continue to make meaningful progress. We believe diverse perspectives drive better decisions, foster creativity and enable stronger business outcomes.
As our organisation evolves into a broader life sciences enterprise, attracting and nurturing world-class talent will remain a strategic priority.

Outlook

While the year brought industry headwinds, we remain confident about the future. The long-term drivers of our businesses – food security, sustainable agriculture, healthcare innovation and growing global outsourcing – continue to present significant opportunities.

As the agrochemical industry moves towards recovery and inventory levels normalise, we believe PI is well positioned to benefit from its strong customer relationships, differentiated portfolio, robust innovation pipeline and manufacturing excellence. Our Biologicals and Health Sciences platforms are emerging as important growth engines, further diversifying our business and strengthening future prospects.

We will continue investing in innovation, technology, manufacturing capabilities and sustainability, while staying focused on operational excellence and long-term value creation.

Looking ahead, our priorities are clear: accelerate innovation, deepen customer partnerships, scale new growth platforms and deliver sustainable value for all stakeholders.

Closing Remarks

Before I conclude, I want to thank all our shareholders for your continued trust, encouragement and support. Your confidence in our vision inspires us to pursue excellence and stay focused on long-term value creation.

I also extend my appreciation to our customers, business partners, employees, regulators and communities for their continued collaboration and support. I would particularly like to thank my fellow Board members for their guidance, wisdom and stewardship as we continue to shape the future of PI Industries.

In particular I would like to express my deepest appreciation and gratitude to Mr. Rajnish Sarna, who, after decades of unstinting service to your Company, has stepped down as Joint Managing Director. He has helped shape your Company's growth over the years and for personal reasons has demitted office. However, he has been kind enough to continue as Non-executive director, so that we do not lose his experience and wisdom totally.

Another fellow director, I would like to thank and express my gratitude is Mr. Arvind Singhal who played a stabilising force as non-executive director bringing his deep knowledge and experience to bear where important in enabling PI Industries to navigate through difficult situations. For personal reasons he is not offering himself for reappointment as a non-executive director. I wish him the best and hope to continue the relationship.

FY 2025-26 presented challenges, but it also reaffirmed the strength of our values, the resilience of our people and the effectiveness of our long-term strategy. As we continue our journey towards becoming a leading life sciences enterprise, we remain committed to innovation, sustainability and creating enduring value for all stakeholders.

On behalf of the Board of Directors, thank you for your participation and continued faith in PI Industries. I wish you and your families good health, happiness and prosperity.

Thank you.